Cytokinetics, Incorporated (CYTK) said on Wednesday that China's National Medical Products Administration has approved Myqorzo for the treatment of adults with obstructive hypertrophic cardiomyopathy.
Under its license and collaboration agreement, Sanofi holds exclusive rights to develop and commercialize Myqorzo for both obstructive and non-obstructive hypertrophic cardiomyopathy in Greater China. The approval in China triggers a $7.5 million milestone payment from Sanofi to Cytokinetics. The company remains eligible to receive up to $142.5 million in additional development and commercial milestone payments, along with royalties in the low-to-high teens on future sales in the region.
Myqorzo is also under regulatory review in the United States, with a Prescription Drug User Fee Act (PDUFA) target action date set for December 26, 2025. In Europe, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending marketing authorization in December 2025, with a final decision expected in the first quarter of 2026.
Cytokinetics shares were up more than 3% in pre-market trading after closing at $62.02, down 0.23%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.